SCHEMBL1625537

SCHEMBL1625537

C[N]CCc1nccs1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8671012 0.79 FDPS (0.47)
SCHEMBL1680301 0.78
SCHEMBL5548976 0.76
SCHEMBL257550 0.76
SCHEMBL3787961 0.74 FDPS (0.47)
SCHEMBL1844671 0.73 CYP2C19 (0.35)
SCHEMBL1843936 0.73 CYP2C19 (0.35)
SCHEMBL9132154 0.72 FDPS (0.39)
SCHEMBL559034 0.72
SCHEMBL1680371 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066040-A1 EP4 INHIBITORS AND USE THEREOF ARRYS THERAPEUTICS INC (US) 2024-02-29 US claimed
US-20210290641-A1 EP4 INHIBITORS AND USE THEREOF ASKAT INC. (JP) 2021-09-23 US claimed
EP-3781162-A1 EP4 INHIBITORS AND USE THEREOF Arrys Therapeutics, Inc. (US) 2021-02-24 EP claimed
WO-2019204257-A1 EP4 INHIBITORS AND USE THEREOF Arrys Therapeutics, Inc. (US) 2019-10-24 WO claimed
US-20190314390-A1 EP4 INHIBITORS AND USE THEREOF ASKAT INC. (JP) 2019-10-17 US claimed
US-20070155732-A1 Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents PFIZER INC. 2007-07-05 US claimed
US-7141580-B2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents PFIZER INC. (US) 2006-11-28 US claimed
EP-1326864-B1 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMA (JP) 2006-03-15 EP claimed
US-20040181059-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ASKAT INC. (JP) 2004-09-16 US claimed
US-6710054-B2 CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS PFIZER INC 2004-03-23 US claimed
EP-1326864-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2003-07-16 EP claimed
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ASKAT INC. (JP) 2002-08-08 US claimed
WO-2002032900-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO claimed
US-20240066040-A1 EP4 INHIBITORS AND USE THEREOF ARRYS THERAPEUTICS INC (US) 2024-02-29 US disclosed
US-20210290641-A1 EP4 INHIBITORS AND USE THEREOF ASKAT INC. (JP) 2021-09-23 US disclosed
US-10973834-B2 EP4 inhibitors and use thereof Arrys Therapeutics, Inc. (US) 2021-04-13 US disclosed
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ASKAT INC. (JP) 2002-08-08 US disclosed
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PFIZER PHARMACEUTICALS INC. (JP) 2002-06-20 US disclosed
WO-2002032422-A2 EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO disclosed
WO-2002032900-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO disclosed